Navigation Links
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Date:1/16/2008

dent of research in metabolic diseases since 2004. While at Roche she oversaw drug discovery programs in diabetes, dyslipidemia and obesity, including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company, which was acquired by Bristol-Myers in 2001, in a variety of positions, including executive director of neuroscience biology and executive director of CNS and obesity research.

"VIA's strategy of addressing significant unmet medical needs of patients with cardiovascular disease by targeting the root cause of vascular inflammation is innovative and has significant potential," said Dr. Taub. "I look forward to supporting the excellent clinical and development work that is taking place and ensuring additional clinical candidates are brought forward."

Before becoming a pharmaceutical executive, Dr. Taub served in a number of academic medicine and clinical research positions. She was a tenured professor of genetics and medicine at the University of Pennsylvania School of Medicine from 1997 to 2001, and she remains an adjunct professor. Earlier she was an assistant professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. She is the author of more than 120 research articles. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The comp
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
6. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... designed to introduce cutting edge communication technology, provide ... platform upgrades. This webinar series demonstrates online communication ... to leverage web conferencing’s most innovative and powerful ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , EATONTOWN, N.J. , Jan. 22 Osteotech, ... of biologic products for regenerative healing, announced today that its Board ... designed to discourage coercive or unfair takeover tactics and to provide ... the event that an unsolicited offer is made to acquire the ...
... Twenty leading US research institutions, patient advocates and biomedical industry ... 2009 Recovery and Reinvestment Act , WASHINGTON , ... anniversary of the Recovery and Reinvestment Act,s enactment on ... patient advocates and biomedical industry have released a detailed report ...
... ... QCam imaging driver for QImaging cameras. This interface provides support for Microsoft,s 64-bit ... faster analysis. , ... (PRWEB) January 20, 2010 -- QImaging, a leading developer and manufacturer of high-performance, ...
Cached Biology Technology:Osteotech, Inc. Adopts Stockholder Rights Plan 2Osteotech, Inc. Adopts Stockholder Rights Plan 3A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 2A Recovery Act Success Story: NIH Funding of Biomedical Innovation Is Creating Jobs, Fueling Industry Growth, and Helping Reduce Long-term Health Care Costs 3QImaging Introduces 64-Bit QCam Driver 2
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:12/24/2014)... 2014  Since its launch in December 2014, the 1U™ ... pain of trying to remember their usernames and passwords through ... their smartphones. To assist people who have struggled to remember ... created 1U and focuses on redefining identity, announced today that ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 31U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... the genetic basis of bipolar disorder, a highly heritable ... depression. The research, published by Cell Press online February ... , identifies a previously unrecognized susceptibility factor for bipolar ... to systematically sort through all the DNA of many ...
... All night long, bats swoop over our landscape consuming ... view. Until recently, scientists have been unable to bring ... genetic techniques, researchers from the University of Bristol and Biodiversity ... environment supporting these elusive creatures. Working at three ...
... With the steep decline in populations of many animal species, scientists ... extinction like those that have occurred just five times during the ... three-quarters or more of all animal species go extinct. In ... Nature , researchers report on an assessment of where mammals ...
Cached Biology News:Scientists identify susceptibility factor for bipolar disorder 2Food forensics: DNA links habitat quality to bat diet 2Earth's sixth mass extinction: Is it almost here? 2Earth's sixth mass extinction: Is it almost here? 3Earth's sixth mass extinction: Is it almost here? 4
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
... Synonym: Dinitro-5,5'-dithiodibenzoic acid , DTNB , ... 396.36 g/mol , *CAS-No.: 69-78-3 ... a product with a reactive grouping not present ... include a reagent which will react directly with ...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
Biology Products: